Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI) (MITCI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02307149
Recruitment Status : Completed
First Posted : December 4, 2014
Last Update Posted : January 18, 2020
Providence Health & Services
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : November 5, 2019
Actual Study Completion Date : November 5, 2019